Scientific and Partnering Events Archive

13-16 June 2013

European Hematology Association (EHA)
Stockholm, Sweden
presented

• 2013 EHA_Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine

10-11 June 2013

Oxford Global:  14th Annual Drug Discovery Leaders Summit
Geneva, Switzerland
presented

31 May - 4 June 2013

ASCO Annual Meeting
Chicago
attended

26-29 May 2013

4th International Symposium on Diffraction Structural Biology
Nagoya, Japan
presented

23-25 May 2013

BIT’s 2nd Annual International Symposium of Hematology
Xi'an, China
presented

14-17 May 2013

EMBO Conference:  Allosteric interactions in cell signaling and regulation
Paris, France
presented

8-10 May 2013

3rd Epigenetics in Drug Discovery
Boston, MA
presented

24-28 April 2013

EASL:  International Liver Congress
Amsterdam, The Netherlands
attended

15-16 April 2013

Proteinase 2013 - 8th RSC-SCI Symposium on Proteinase Inhibitor Design
Basel, Switzerland
presented

7-11 April 2013

ACS National Meeting & Exposition
New Orleans, LA
presented

6-10 April 2013

AACR Annual Meeting
Washington, DC
presented

• 2013 AACR_Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer
• 2013 AACR_SGI-110 induces Cancer Germline (CG) antigen expression in Acute Myeloid Leukemia cells
• 2013 AACR_In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent
• 2013 AACR_Evaluation oral bioavailability and intermittent dosing schedule for PD effects by SGI-110
• 2013 AACR_Phase 2 study of amuvatinib, RAD51 inhibitor in combo with platinum-etoposide in R/R SCLC
• 2013 AACR_AT-IAP, a dual cIAP1 and XIAP antagonist with oral antitumor activity in melanoma models

14 March 2013

SMR:  Therapeutic Opportunities in Infectious Diseases
London
presented

4-6 March 2013

International Congress on Targeted Anticancer Therapies (TAT) 2013
Paris, France
presented

• 2013 TAT_IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT

3-5 March 2013

Fragments 2013 - Fourth RSC-BMCS Fragment-based Drug Discovery meeting
Oxfordshire, UK
presented

24-26 January 2013

2013 Gastrointestinal Cancers Symposium
San Francisco, CA
presented

• 2013 GI Conference: AT13387, A Novel Non-Ansamycin Inhibitor of HSP 90 is Active against GIST

20-24 January 2013

MBCF:  11th Winter Conference on Medicinal and Bioorganic Chemistry
Steamboat Springs, CO
presented

18-21 January 2013

Clinical Translation of Epigenetics in Cancer Therapy
Asheville, NC
presented

16-17 January 2013

PPI-Net Conference- Protein-Protein Interactions: Emerging Science & Therapeutic Potential
London, UK
presented

8-11 December 2012

American Society of Hematology (ASH) 2012 Annual Meeting and Exposition
Atlanta, GA
presented

• 2012 ASH_Results from Dose Escalation Phase of Randomized Phase 1-2 FIH Study of SGI-110

11-13 November 2012

PSDI 2012
Paris, France
presented

9-13 November 2012

AASLD:  The Liver Meeting
Boston, MA
presented

• 2012_AASLD_Discovery of AT26893, novel alloseteric inhibitor of the regulation of HCV NS3/4a protein

8-9 November 2012

GTC:  Protein Kinases and Drug Design
Boston, MA
presented

6-9 November 2012

24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Dublin, Ireland
presented

• 2012 EORTC_Characterization of a Potent XIAP & cIAP1 Dual Antagonist in Melanoma and Leukemia
• 2012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models
• 2012 EORTC: SGI-110, enhances sorafenib activity and alters methylation signature of HCC Cell lines

10-14 October 2012

Hematologic Malignancies Conference
Houston, TX
attended

5-9 October 2012

19th International Symposium on Hepatitis C Virus and Related Viruses
Venice, Italy
presented

1-2 October 2012

Sachs Associates:  12th Annual Biotech in Europe Investor Forum
Zurich, Switzerland
presented

26-28 September 2012

Drug Design 2012
Oxford, UK
presented

23-26 September 2012

Fragment-based Lead Discovery Conference 2012
San Francisco, CA
presented

6-8 September 2012

2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
Chicago, IL
presented

• 2012 ThoracicSympm_HSP90 Inhibitor AT13387 Effective in Mutant EGFR and ALK-Positive NSCLC Models

5-6 September 2012

ELRIG:  Drug Discovery 2012
Manchester, UK
presented

5-8 September 2012

Glasgow 2012:  European Congress of Immunology
Glasgow, Scotland
presented

2-6 September 2012

EFMC-ISMC 2012:  22nd International Symposium on Medicinal Chemistry
Berlin, Germany
presented

24-27 August 2012

7th International Conference:  Inhibitors of Protein Kinases (IPK)
Warsaw, Poland
presented

19-23 August 2012

244th American Chemical Society National Meeting & Exposition
Philadelphia, PA
presented

12-17 August 2012

FASEB:  Biological Methylation:  From DNA and Histones to Disease
Snowmass Village, CO
presented

6-11 August 2012

ECM27:  The 27th European Crystallographic Meeting
Bergen, Norway
presented

5-10 August 2012

Gordon Research Conference:  Medicinal Chemistry
New London, NH
presented

17-20 July 2012

21st Italian National Meeting in Medicinal Chemistry
Palermo, Italy
presented

4-6 July 2012

RICT 2012:  48th International Conference on Medicinal Chemistry
Poitiers, France
presented

2-5 July 2012

The Physiological Society Meeting
Edinburg, UK
presented

18-22 June 2012

BIO International Convention
Boston, MA
attended

14-15 June 2012

Apoptosis and Cancer
Cambridge, UK
presented

13 June 2012

RSC:  Younger Members Symposium 2012
Nottingham, UK
presented

7-8 June 2012

GTC:  6th Drug Design and Medicinal Chemistry
San Diego, CA
presented

6-9 June 2012

CHI Structure-Based Drug Design
Boston, MA
presented

1-6 June 2012

ASCO Annual 2012 Meeting
Chicago, IL
presented

• 2012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory solid tumors
• 2012 ASCO: Phase I StudyAssessing QDx2 schedule of AT13387 in Advanced Solid Tumors
• 2012_ASCO: Phase I trial of AT9283 in children & adolescents with relapsed & refractory solid tumour

30-31 May 2012

2nd Epigenetics in Drug Discovery
Boston, MA
presented

25-29 May 2012

EMBO:  Cellular Signaling & Molecular Medicine
Cavtat-Dubrovnik
presented

21-22 May 2012

Protein Kinase 2012:  Signalling Success:  5th SCI RSC Symposium on kinase inhibitor design
Cambridge, UK
presented

15-16 May 2012

BioEquity Europe 2012
Frankfurt, Germany
presented

13-18 May 2012

Noordwijkerhout-Camerino-Cyprus Symposium
Amsterdam, The Netherlands
presented

9-12 May 2012

Molecularly Targeted Therapies:  Mechanisms of Resistance (AACR)
San Diego, CA
presented

22-24 April 2012

The 1st Israeli-UK Medicinal Chemistry Conference
Rehovot, Israel
presented

18-23 April 2012

EASL The International Liver Congress 2012
Barcelona, Spain
presented

• 2012 EASL_abst 878: Preclin characterisation of allosteric inhibitor of HCV NS3/4a protein
• 2012 EASL abst 871: Fragment based discovery & genotypic profiling of a series of antiviral agents

18-20 April 2012

CHI HCV Drug Discovery
San Diego, CA
presented

17-19 April 2012

CHI Fragment-Based Drug Discovery
San Diego, CA
presented

16-20 April 2012

British Crystallographic Assocation Spring Meeting 2012
Warwick, UK
presented

31 March - 6 April 2012

American Association for Cancer Research Annual Meeting 2012
Chicago, IL
presented

• 2012 AACR_Interim results from randomized Phase 1-2 FIH study PK/PD guided escalating doses SGI-110
• 2012 AACR_abst 4077: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer
• 2012 AACR_abst 4076: SGI-110, a novel SQ second generation DNA hypomethylating agent
• 2012 AACR_Scale up and development of a process for a low volume subcutaneous formulation of SGI-110
• 2012 AACR_AT13387, HSP90 inhibitor effective in vemurafenib-sensitive and -resistant melanoma models
• 2012 AACR_abst 2018: Discovery of potent dual inhibitors of both XIAP and cIAP using fragment based
• 2012 AACR_abst 2315 Pharmacodynamic and anti-tumor activity of fragment-derived inhibitors of MetAP2
• 2012 AACR_abst SY03-01: Pyruvate kinase M2: linking glycolysis to amino acid biosynthesis
• 2012 AACR_abst 3762: Second generation PIM inhibitor exhibits potent activity in tumor models
• 2012 AACR_abst 2485: Combined Src and aurora kinase inhibition in medulloblastoma
• 2012 AACR_abst 3226: PKM2 metabolic activators inhibit lung adenocarcinoma xenograft growth

25-30 March 2012

ACS Spring 2012 National Meeting
San Diego, CA
presented

19-22 March 2012

BIO-Europe Spring 2012
Amsterdam, The Netherlands
presented

19-23 March 2012

New Approaches in Drug Design & Discovery, Workshop
Marburg, Germany
presented

13-15 March 2012

Discovery Chemistry Congress 2012
Munich, Germany
presented

8-11 March 2012

International Congress on Targeted Anticancer Therapies (TAT) 2012
Amsterdam, The Netherlands
presented

• 2012 TAT_Discovery of Dual Antagonist of both XIAP and cIAP Using Fragment Based Drug Discovery
• 2012 TAT_Anti-Angiogenic Activity of Fragment-Derived Inhibitors of METAP2

8-10 March 2012

CALBIO 2012
San Fancisco, CA
attended

9-12 January 2012

Biotech Showcase 2012
San Francisco, CA
presented

9-10 December 2011

Royal Society of Chemistry: 5th Biological and Medicinal Chemistry Symposium for Postgraduates
Cambridge
presented

4-9 December 2011

HEP DART 2011
Koloa, Hawaii
presented

• 2011 HepDart_In Vitro Combination of HCV NS3 Allosteric Inhibitor w. Direct-Acting Antivirals
• 2011 HepDart_Novel Allosteric Binding Site on Full Length HCV NS3/4a by Frag Based Xray

12-17 November 2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer
San Francisco, CA
presented

• 2011 EORTC_AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant GIST Models
• 2011 EORTC_Mouse PK of AKT Inhibitor CCT128930 from Caudal Dried Blood Spots
• 2011 EORTC_2nd Generation PIM Inhibitors Exhibit Improved Activity in Solid Tumor Models

7-9 November 2011

GDDIS 2011: Global Discovery and Development Innovation Summit
Orlando
presented

4-9 November 2011

AASLD: The Liver Meeting: 62nd Ann. Mtg. of the American Association for the Study of Liver Diseases
San Francisco
presented

• 2011 Liver M_Allosteric Binding Site on Full Length HCV NS3/4a by Fragment Based Xray
• 2011 Liver M_Replicon Validation of HCV NS3 Allosteric Inhibitors, New Therapeutic Approach

31 October - 3 November 2011

BIO-Europe
Dusseldorf
presented

20-23 October 2011

Nature Chemical Biology Symposium 2011: Cancer Chemical Biology
Boston
presented

16-20 October 2011

Ausbiotech
Adelaide
presented

11-15 October 2011

BIO-China
Shanghai
presented

9-12 October 2011

BioPartnering Europe
London
presented

2-8 October 2011

29th Noordwijkerhout Camerino Cyprus Conference on Medicinal Chemistry
Cyprus
presented

23-28 September 2011

ECCO: The 2011 European Multidisciplinary Cancer Congress
Stockholm
presented

21-24 September 2011

Pharmaceutical Strategic Alliances
New York
presented

11-15 September 2011

16th SCI-RSC Medicinal Chemistry Symposium
Cambridge
presented

7-13 August 2011

The 2011 Medicinal Chemistry Gordon Conference
New London, NH
presented

• Case Histories in Fragment Based Drug Discovery

2-7 April 2011

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
Orlando
presented

• Fragment Based Drug Discovery of Selective Inhibitors of Fibroblast Growth Factor Receptor (FGFr)